IDH2 and central nervous system cancer: Another study provided evidence that the PARP1-associated DNA reparation pathway was compromised in IDH-mutant gliomas due to decreased NAD+ content; importantly, targeting the PARP1 DNA repair pathway markedly sensitized IDH1-mutant gliomas to temozolomide [409].